Akebia Therapeutics, Inc. - AKBA STOCK NEWS

Akebia Therapeutics (AKBA) has received marketing authorization from the European Commission for Vafseo™ (vadadustat), an oral treatment for symptomatic anaemia associated with chronic kidney disease (CKD) in adults on dialysis. This approval, effective across all 27 EU member states along with Iceland, Norway, and Liechtenstein, is a significant milestone for Akebia and aims to assist over 200,000 dialysis patients in Europe. Vafseo is available in 150 mg, 300 mg, and 450 mg film-coated tablets, providing an alternative treatment option. The approval follows a favorable opinion from the European Medicines Agency in February 2023 and is based on a robust clinical program involving over 7,500 patients. Akebia plans to partner with a European entity to expedite the drug's availability to patients in need.

Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced a stockholder information session on April 21, 2023, at 8:00 a.m. ET. The meeting aims to discuss a proposed reverse stock split to comply with Nasdaq's minimum bid price rule and avoid delisting. A special meeting on May 4, 2023, will allow stockholders to vote on this proposal. Stockholders are encouraged to submit questions by April 19 and can register for the webcast on Akebia's website. They can also vote online, by phone, or by mail, with instructions provided in the revised proxy materials sent on March 17, 2023. Participation is critical for stockholders, as the board recommends voting 'FOR' the proposals to ensure compliance and enhance company stability.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced the adjournment of its special meeting of stockholders originally scheduled for April 11, 2023. The meeting will reconvene on May 4, 2023, at 10:00 a.m. Eastern Time. The adjournment allows the company to gather additional proxies necessary for voting on proposals in its revised definitive proxy statement filed on March 17, 2023. Stockholders are encouraged to vote by May 3, 2023, as the board recommends voting 'FOR' all proposals. Proxies submitted prior will remain valid unless revoked. The meeting's record date remains February 16, 2023, and details are available on the SEC and proxy voting websites.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in the National Kidney Foundation (NKF) Spring Clinical Meetings 2023, taking place from April 11 to April 15 in Austin, Texas. During this event, Akebia will present posters focusing on critical research related to kidney disease, highlighting topics such as inpatient admission and mortality rates among Medicare patients with dialysis-dependent chronic kidney disease (CKD) and blood transfusion rates. The company aims to enhance the lives of individuals affected by kidney disease and is committed to showcasing its findings at this prominent clinical forum. Attendees can visit Akebia's booth (#801) to learn more about their initiatives and research findings.

On April 4, 2023, Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to a new employee, totaling 4,000 shares. The options were provided as an inducement for the employee's recruitment and adhere to Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $0.56 per share, matching the stock's closing price on the grant date. These options will vest over a period of four years, with a quarter vesting on the first anniversary. Each option has a term of ten years and is governed by Akebia's stock option agreement.

Akebia Therapeutics (Nasdaq: AKBA) reported positive top-line results from the FO₂CUS study, evaluating vadadustat for treating anemia in hemodialysis patients. The study demonstrated that vadadustat met both primary and secondary efficacy endpoints, proving non-inferiority to the long-acting erythropoiesis-stimulating agent (ESA), Mircera, when used three times weekly. Additionally, vadadustat exhibited a safety profile comparable to Mircera. The trial involved 456 patients, with results indicating sufficient management of hemoglobin levels, suggesting potential as an oral alternative for current treatment options.